Topics
Business & Finance
-
Monday - November 2, 2009
Successful purchase of trait platform with extensive product pipeline:
Bayer CropScience completes acquisition of biotech company Athenix Corp.
Purchase price of USD 365 million plus milestones
-
Tuesday - October 27, 2009
News Conference Call for the Third Quarter of 2009
Address by Werner Wenning
Chairman of the Board of Management
-
Tuesday - October 27, 2009
Bayer AG News Conference Call and Report for the Third Quarter of 2009
-
Tuesday - October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed
-
Thursday - October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
-
Friday - October 9, 2009
Improvement in orders
Bayer MaterialScience AG ends reduced working hours at German sites
Rates of pay to be raised again / Solidarity-based solution has proved its worth / Opening clause in collective agreement applied from February to the end of October 2009
-
Monday - October 5, 2009
Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):
Bayer’s novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding
Results also confirm significant improvement in blood iron levels
-
Wednesday - September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany
-
Tuesday - September 22, 2009
Once again included in the Carbon Disclosure Leadership Index
Bayer honored as world’s best company in climate protection
Index organizer Dickinson: “Listed companies are the best placed to prosper in a low carbon economy of the future” / Bayer CEO Wenning: “Top position is high praise for our strategic alignment” / Investors and analysts specifically interested in companies' climate strategies
-
Thursday - September 17, 2009
Greater focus on future technologies:
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018
BioScience sales of EUR 1.4 billion targeted for 2018 / Biotech licensing agreements tap into business potential in excess of EUR 500 million / Peak sales potential of new crop protection actives raised to EUR 1.25 billion
-
Thursday - September 17, 2009
Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions
-
Tuesday - September 15, 2009
Bayer Supervisory Board decides company’s future management line-up:
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
Werner Wenning extends his contract by eight months / CFO Klaus Kühn to retire on April 30, 2010 / Werner Baumann to be new CFO / BHC CEO Arthur J. Higgins to leave Bayer at his own request
-
Friday - September 4, 2009
Bayer again included in the Dow Jones Sustainability World Index:
Bayer remains “best in class” in sustainability
Significance of sustainable investment is continuing to rise
-
Thursday - September 3, 2009
Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients
Phase III compound represents potential therapy for life-threatening condition
-
Sunday - August 30, 2009
Bayer Committed to Prevention of Arterial Thrombosis:
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation / Bayer Schering Pharma supports Thrombosis Research Institute’s launch of GARFIELD – a global patient Registry to evaluate ‘real life’ outcomes in the prevention of stroke in patients with Atrial Fibrillation / Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need.
-
Wednesday - August 19, 2009
Trait platform with extensive product pipeline to deliver innovative solutions for farmers:
Bayer CropScience acquires US biotech company Athenix Corp.
-
Wednesday - August 19, 2009
New Levitra® formulation submitted for registration in the EU
First orodispersible tablet for the treatment of erectile dysfunction
-
Wednesday - July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
HealthCare strong – further growth at CropScience – MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) / Earnings targets for full year 2009 confirmed
-
Wednesday - July 22, 2009
Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies
-
Tuesday - July 21, 2009
Long-term cooperation with leading Australian research institute CSIRO:
Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cereals
Superior solutions for wheat farmers could be available as early as 2015
Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection